key: cord-0763936-dsatup57 authors: Becerra, José; Duran, Ivan title: Inflammation, a common mechanism in frailty and COVID‐19, and stem cells as a therapeutic approach date: 2021-08-03 journal: Stem Cells Transl Med DOI: 10.1002/sctm.21-0074 sha: e7596b5ad3470a759fc1583e2ff6312f8efc61fc doc_id: 763936 cord_uid: dsatup57 As our life expectancy increases, specific medical conditions appear, and new challenges are met in terms of global health. Frailty has become a medical and scientific concept to define pathologies where inflammation, depressed immune system, cellular senescence, and molecular aging converge. But more importantly, frailty is the ultimate cause of death that limits our life span and deteriorates health in an increasing proportion of the world population. The difficulty of tackling this problem is the combination of factors that influence frailty appearance, such as stem cells exhaustion, inflammation, loss of regeneration capability, and impaired immunomodulation. To date, multiple research fields have found mechanisms participating in this health condition, but to make progress, science will need to investigate frailty with an interdisciplinary approach. This article summarizes the current efforts to understand frailty from their processes mediated by inflammation, aging, and stem cells to provide a new perspective that unifies the efforts in producing advanced therapies against medical conditions in the context of frailty. We believe this approach against frailty is particularly relevant to COVID‐19, since people in a state of frailty die more frequently due to the hyperinflammatory process associated with this infection. ing proportion of the world population. The difficulty of tackling this problem is the combination of factors that influence frailty appearance, such as stem cells exhaustion, inflammation, loss of regeneration capability, and impaired immunomodulation. To date, multiple research fields have found mechanisms participating in this health condition, but to make progress, science will need to investigate frailty with an interdisciplinary approach. This article summarizes the current efforts to understand frailty from their processes mediated by inflammation, aging, and stem cells to provide a new perspective that unifies the efforts in producing advanced therapies against medical conditions in the context of frailty. We believe this approach against frailty is particularly relevant to COVID-19, since people in a state of frailty die more frequently due to the hyperinflammatory process associated with this infection. aging, COVID-19, frailty, immunomodulation, inflammation, mesenchymal stem cell, MSC, regeneration, stem cell exhaustion In recent years, the authors have assisted with important advances in the understanding of stem cell exhaustion as a wide mechanism of disease responsible for age-related health deterioration. On the other hand, the stem cell role in immunomodulation has emerged as one of the most promising effects of stem cell therapy targeting the inflammatory process. These two separate topics are now emerging under a common theme and need to be addressed as a whole. The present study intends to put in perspective the common ground among these concepts and offers a future perspective of the next steps in the search for therapeutic approaches to frailty. There is no doubt that infection with SARS-CoV-2, the coronavirus responsible for COVID-19, causes a high mortality rate in the elderly, especially among men presenting age-related comorbidities. 1, 2 This has been easily justified by age-related pathologies, which are inherently associated with systemic and subclinic chronic inflammation (inflammaging) and acquired immune system impairment (immunosenescence). These agerelated mechanisms follow four age-related medical events that are associated with increased mortality 3 : (a) systemic inflammation, (b) a blunted acquired immune system, (c) downregulation of ACE2, and (d) accelerated molecular aging. These are all well-established correlations that we unfortunately do not understand enough to develop specific and more efficient therapies. In an effort to understand these factors, the frailty concept was coined. Frailty (from the Latin "fragilis" means "easily broken") is defined as a clinical syndrome in which several of the following criteria are present: rapid weight loss, self-reported exhaustion, weakness (measured by grip strength), slow walking speed, and limited physical activity. 4 However, the "frailty" term was used first by Vaupel and colleagues 5 as a way to "measure" the variability in the risk of death among people of the same age. 6 From a more mechanistic point of view, frailty begins when aged individuals deteriorate following what some have called the seven pillars of aging 7 or the nine hallmarks of aging. 8 These can be summarized as genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. These aging processes are interconnected and thus some can induce others. In this review, we focus on stem cell exhaustion, a well described process during regeneration but less clear regarding frailty. We also discuss stem cell therapies as one of the few modern strategies that has promised to tackle this stem cell dysfunction, not only as a therapy for frailty but also related emerging diseases like COVID-19. Since the discovery of pluripotency by Thompson and colleagues in early human blastocyst stem cells (embryonic stem cells, ESCs) and their abilities to differentiate into the three blastodermic lineages, 9 there has been an explosion in stem cell research for therapeutic strategies and even the emergence of a new discipline, regenerative medicine, considered by some as a new medical field called Regenology. 10 This race for stem cell applications has been a "roller coaster" with more wishes than clinic realities, but after 20 years of research, the field is finally obtaining solid results through several approaches. After the discovery of ESC pluripotency, the field also turned to the adult stem cells (ASCs), tissue specific stem cells that show a more restricted lineage. These cells respond to tissue damage through life by proliferation and differentiation, suffering telomere attrition, and finally reduction of the proliferative capacity. Inside this group, Among all the ASC types, MSCs were the first to be described and used for regenerative studies, although, their applications have always been a subject of an intense debate and controversy. 12 They were described and named by Caplan 13, 14 when HSC were the only adult stem cells known to science, but controversy began even from the moment in which the term MSC was coined. Nowadays, the acronym MSC can also mean "marrow/multipotent/mesodermal, stromal/stem, cells," according to criteria of location, power, embryonic origin, morphological features, and so forth. Finally, Caplan chose the name "mesenchymal stem cell" because mesenchyme is a tissue characterized by weakly associated unpolarized cells with an abundant extracellular matrix, and for their in vitro clonability and multipotency. 15 Even so, recently, Caplan proposed to adapt the meaning of MSC to "medicinal signaling cell," saving the widely used acronym but providing to these controversial cells a new clinical feature from its paracrine function by which these cells are able to repair and immunomodulate upon injury or inflammation through their secretory signals. 16 Nevertheless, mesenchymal stromal/stem cell are the most widely used. Perhaps before abandoning its mesenchymal name, it would be convenient to look deeper into the mesenchymal area of the human body, because even if MSCs are called differently, their function still happens in that specific tissue environment. This widely located compartment is able to reach and expand virtually through the whole body and its ubiquitous presence provides a place for the immune system to act and propagates signals that trigger the inflammatory response. The mesenchyme is generated as an embryonic tissue, with features of loose connective, with an abundant and hydrated extracellular matrix made of thin fibers and well-spread unspecialized cells. It is mesodermal in origin and gives rise to cardiovascular, musculoskeletal, mesothelial, and lymphatic systems. Thus, if we try to understand the mechanisms that rule the immunological response, we must understand its physiopathological context through its wide distribution in the organism. Inflammation (from Latin: inflammatio: kindling or setting on fire) is a common manifestation of many diseases. In fact, it is an unspecific response against environmental aggressions. Interestingly, inflammation only happens in vascularized connective tissues with the goal of isolating and removing harmful stimuli and inducing damaged tissue repair. It is considered an innate immune mechanism that works similarly in most situations in contrast with the adaptive immune response, specific to each situation. 17 Our current medical knowledge indicates that aging correlates with chronic systemic inflammation, even if it does not always show clinical manifestations. This has been called inflammatory aging and it is accompanied by a deterioration of the immune system, also called immunosenescence. 3, 18 Thus, aging mediates an alteration of the previously described "mesenchymal territory" that predisposes to chronic inflammation by failure of the mechanisms that maintain the homeostatic state of early ages. Interestingly, this happens more often in men than women, 19 which correlates with the higher mortality rates of males in medical diseases, such as COVID- 19. 2 At the molecular level, MSCs are known to mediate inflammation; however, two MSC phenotypes can switch between proinflammatory and anti-inflammatory regulation. So, a key aspect of MSC use in inflammation is to correctly manipulate MSCs to favor an anti-inflammatory effect. A possible approach is explored by Mounayar Senescence in MSCs has been documented during aging in vivo 36 and it limits MSC numbers in organisms of different ages. While the bone marrow of newborns presents an average of one MSC per 10 000 cells, this proportion decreases drastically with age to one in 2 million by the age of 80. 13 This could explain the alteration of tissue homeostasis and the occurrence of age-related diseases. 37 MSC senescence is characterized by cell cycle arrest in G1, changes in morphology, and increases in senesce markers β-galactosidase and SA-α-Fuc (senescence-associated lysosomal α-L-fucosidase). Senescence also alters specific surface markers such as Stro-1 and CD106, correlating with the number of division and donor age. 36 MSC senescence is also associated with increased reactive oxygen species (ROS). 38 Cell culture studies from people 20 to 70 years old demonstrated that older MSCs showed lower proliferation rates, less chondrogenic and osteogenic potential in favor of an increased adipogenesis, and increased signals related to senescence. 39 As explained before, frailty is defined as the progressive functional decline and increased vulnerability to stress resulting from decreased physiological reserve and resilience. 40 Frailty has a high socioeconomic impact with a prevalence of 15% above 65 years of age. A frailty index (FI) has been proposed as a measurement of the multidimensional accumulative factors that lead to disability and death. 41, 42 However, no effective therapeutic approach is available to reduce or delay the consequences of frailty. One of the bestestablished facts about the mechanism of frailty is its correlation with stem cell exhaustion. Probably all endogenous adult stem cells are involved in such responsibility, but more are the MSCs located in mesodermal tissues in their network of capillaries and arterioles from which they can cover a vast and ubiquitous multi-organ territory. The MSC/pericyte system described above decreased with age and could be necessary protection for vascularized tissues. That is why the use of MSCs is currently being explored using multiple approaches as the logical and specific therapy against the frailty effects through their ability to migrate into injured and inflamed sites, differentiate into multiple tissue specific lineages, and have immunomodulatory effects. Nonetheless, this type of therapy still needs improvement in terms of manufacturing and delivery through cell engineering to fully use the immunomodulatory properties, homing, and efficacy of MSCs. 43 Table 1 ). The downside of these studies is the lack of consistency among the methodology used, with significant variations in the number of infused cells, cell origin, quality of the donor and their MSCs, and hemocompatibility, all common problems of MSC therapies. 43 Tolerance to these treatments, demonstrated in hundreds of patients in multicentric trials, and the reversion of some parameters compromised in frailty make these therapies a well-founded hope. However, to progress in this approach, the field will need the establishment of new and consistent animal models, as well as a better and systematized diagnosis of frailty conditions through more sensible and validated biomarkers. 40 One set back of this approach has been the allograft rejection, which limits the effect of MSC treatments. Promising strategies to bypass to this problem are the use of MSCs' secretome/exosome (discussed later) or generation of an immunoprivileged site of application where MSCs can survive long enough to perform immunomodulation. 50 7 | MSC THERAPIES AGAINST COVID-19: CELLS, SECRETOME, AND EXOSOME The SARS-CoV-2 pandemic has challenged the scientific communities to adapt and innovate at an accelerated rate to find effective treatments against a physiophatologic mechanisms to which we were not prepared. One of new advanced therapies explored is MSC treatment (Figure 2 ). COVID-19 is mediated through an hyperinflammatory response associated with the cytokine release syndrome and is associated acute respiratory syndrome prompted the exploration of many immunomodulatory new strategies. [51] [52] [53] [54] [55] [56] The initial therapies against the worst cases of COVID-19, those presenting acute respiratory distress syndrome or ARDS, selectively targeted cytokines with limited results. Now we know that to get a true effect on the hyperinflammatory response we need to target a wide set of inflammatory signals and our most effective treatments have ended being classic anti-inflammatories, such as dexamethasone. 57 The key seems to be controlling the feedback loop that transforms a normal cytokine response into a cytokine storm. This concept has taken us from limited results from early attempts to control cytokine release to modulate the adaptive immune response to avoid the secondary cytokine release. 62 The first study started in China in January 2020, injecting 1 million MSC cells/kg in the blood stream. This very preliminary trial concluded manifesting a pulmonary function improvement, peripheral lymphocyte increase, decrease of C-reactive protein as well as cytokine releasing cell types after 3 days of treatment in the seven treated patients. 63 Authors on the study also reported TNF-α decrease and IL-10 increase and concluded that MSCs seemed to inhibit hyper-activation of the immune system. F I G U R E 2 Mesenchymal stem cell (MSC) therapy is capable of reducing the hyperinflammatory response in cases of severe COVID-19. SARS-CoV-2 infection causes severe COVID-19 by inflammation associated to neutrophilia (including NETS-neutrophil extracellular traps) and pro-inflammatory macrophagic response. MSC treatment specially targets lungs and provides of in situ and systemic immunomodulation, antimicrobial and other trophic effects (see Figure 1 ) supporting an anti-inflammatory profile of macrophages and appropriate coordination of T and B cells to fight against SARS-CoV-2 infection. MSC mitogenic, angiogenic, and anti-apoptotic effects drive resident cells into tissue regeneration. MSC anti-scarring effects avoid fibrosis in lung, an adverse side effect in COVID-19 disease Although results from MSC therapies are promising, this strategy also presents important limitations, such as slow production, low profitability, demanding quality controls, and short expiration dates. These factors limit this kind of therapy upon the immediate need and the need of massive treatments in pandemic times. 65 74 They show specific action on macrophage activation inducing an anti-inflammatory profile. [75] [76] [77] Besides, it is possible to induce the therapeutic response of the secreting MSC to produce a certain exosome profile with more anti-inflammatory signals. 78, 79 The use of exosomes instead of cells also avoids the risks of the later (like their tumorigenic effect) and provide logistic advantages, such as rapid scalable production and a long shelf-life. 80 The use of exosomes is rapidly being considered a viable therapeutic strategy and 91 clinical trials are already registered at a global scale from which 12 are exosome treatments from MSCs (ClinicalTrials.gov). One of these uses allogeneic MSC exosomes for COVID-19 cases with ARDS, injecting 24 patients with their exosome product (ExFlo) to study safety and initial efficacy. 81 Preliminary results from this study showed a reduction in hypoxic state by altered pulmonary function and immune markers recovery without adverse effects. In summary, MSC research during the last decades has been a rollercoaster of promises, controversies, and unexpected discoveries, which have changed our perspective of their potential use as a therapy for different human conditions and diseases. We believe that although the original promises have not been met, the intense dedication to their study has opened new alternatives to use their less known para- Program, CIBER Actions, the Instituto de Salud Carlos III; Regional Government of Andalusia (PAIDI group BIO-217); University of Malaga (Plan Propio). Figure 2 was created with Biorender.com. The authors declared no potential conflicts of interest. JB: conception, design and writing; ID: conception, design and writing, final approval. The data that support the findings of this study are available from the corresponding author upon reasonable request. Ivan Duran https://orcid.org/0000-0001-6097-0402 From causes of aging to death from COVID-19 Inflamm-aging: why older men are the most susceptible to SARS-CoV-2 complicated outcomes Inflamm-aging. An evolutionary perspective on immunosenescence Cardiovascular health study collaborative research group. Frailty in older adults: evidence for a phenotype The impact of heterogeneity in individual frailty on the dynamics of mortality Geroscience: linking aging to chronic disease The hallmarks of aging Embryonic stem cell lines derived from human blastocysts Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors Clear up this stem-cell mess Mesenchymal stem cells Marrow stromal stem cells Multilineage potential of adult human mesenchymal stem cells Mesenchymal stem cells: time to change the name! STEM CELLS TRANSLATIONAL MEDICINE Basic immunology-functions and disorders of the immune system The integration of inflammaging in age-related diseases A gender-dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevity PI3kα and STAT1 interplay regulates human mesenchymal stem cell immune polarization Chlorzoxazone, a small molecule drug, augments immunosuppressive capacity of mesenchymal stem cells via modulation of FOXO3 phosphorylation Time-dependent LPS exposure commands MSC immunoplasticity through TLR4 activation leading to opposite therapeutic outcome in EAE Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes A perivascular origin for mesenchymal stem cells in multiple human organs Mesenchymal and haematopoietic stem cells form a unique bone marrow niche Adult SVZ stem cells lie in a vascular niche: a quantitative analysis of niche cell-cell interactions Mesenchymal stem cells regulate melanoma cancer cells extravasation to bone and liver at their perivascular niche In search of the in vivo identity of mesenchymal stem cells The MSC: an injury drugstore Embryonic stem cell extracts improve wound healing in diabetic mice The MSC curtain that stops the immune system Pericytes, mesenchymal stem cells and their contributions to tissue repair Antibacterial activity of human mesenchymal stem cells mediated directly by constitutively secreted factors and indirectly by activation of innate immune effector cells Mesenchymal stem cell perspective: cell biology to clinical progress Mesenchymal stem cells for the treatment of idiopathic pulmonary fibrosis Senescence of mesenchymal stem cells Promise and problems in relating cellular senescence in vitro to aging in vivo Endogenous ROS levels are increased in replicative senescence in human bone marrow mesenchymal stromal cells Designing drug trials for frailty: ICFSR Task Force A global clinical measure of fitness and frailty in elderly people High prevalence of physical frailty among community-dwelling malnourished older adults-a systematic review and meta-analysis Mesenchymal stromal cell therapeutic delivery: translational challenges to clinical application Stem cell transplantation for frailty Mesenchymal stem cell therapy for aging frailty Frailty and rejuvenation with stem cells: therapeutic opportunities and clinical challenges Allogeneic mesenchymal stem cells ameliorate aging frailty: a phase II randomized, doubleblind, placebo-controlled clinical trial Attenuation of frailty in older adults with mesenchymal stem cells Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology Clinical and immunological features of severe and moderate coronavirus disease 2019 Clinical features of patients infected with 2019 novel coronavirus in Wuhan Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis COVID-19: consider cytokine storm syndromes and immunosuppression Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: gleaning insights for possible use in COVID-19 Dexamethasone in hospitalized patients with Covid-19-preliminary report Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice Inflammasomes and pyroptosis as therapeutic targets for COVID-19 Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis Functional exhaustion of antiviral lymphocytes in COVID-19 patients Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure Adiposederived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study Mesenchymal stem cell therapy for COVID-19: present or future Cell-based therapy to reduce mortality from COVID-19: systematic review and meta-analysis of human studies on acute respiratory distress syndrome Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: the case for compassionate use Mesenchymal stromal cell secretome for severe COVID-19 infections: premises for the therapeutic use The mesenchymal stem cell secretome: a new paradigm towards cell-free therapeutic mode in regenerative medicine Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine Immunomodulation by mesenchymal stem cells and clinical experience Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine Applying extracellular vesicles based therapeutics in clinical trials-an ISEV position paper Comparative analysis and characterization of soluble factors and exosomes from cultured adipose tissue and bone marrow mesenchymal stem cells in canine species TNF-α and INF-γ primed canine stem cell-derived extracellular vesicles alleviate experimental murine colitis Pro-inflammatory stimuli enhance the immunosuppressive functions of adipose mesenchymal stem cells-derived exosomes Exosomes derived from human umbilical cord mesenchymal stem cells ameliorate IL-6-induced acute liver injury through miR-455-3p Priming approaches to improve the efficacy of mesenchymal stromal cellbased therapies Inflammatory priming enhances mesenchymal stromal cell secretome potential as a clinical product for regenerative medicine approaches through secreted factors and EV-miRNAs: the example of joint disease Concise review: MSC-derived exosomes for cell-free therapy Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19 Inflammation, a common mechanism in frailty and COVID-19, and stem cells as a therapeutic approach